Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z739
UPID:
YTHD3_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z739; B3KXL4; Q63Z37; Q659A3
Background:
YTH domain-containing family protein 3 plays a pivotal role in RNA metabolism, specifically recognizing and binding N6-methyladenosine (m6A)-containing RNAs. This modification is crucial for mRNA stability and processing. The protein is involved in the degradation of m6A-containing mRNAs, cellular differentiation, and acts as a negative regulator of type I interferon response. It also binds to circular RNAs and promotes the formation of phase-separated compartments like P-bodies.
Therapeutic significance:
Understanding the role of YTH domain-containing family protein 3 could open doors to potential therapeutic strategies.